Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From the National Cancer Institute, Demonstrating PT-112's Immune Activation in Thymic Epithelial Tumors
/PRNewswire/ -- The National Cancer Institute (NCI), part of the National Institutes of Health, under formal collaboration with Promontory Therapeutics Inc., a...